
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio Inc. presents an attractive investment opportunity due to its promising clinical-stage programs, particularly with GRI-0621 and GRI-0803, targeting serious immune-related disorders. The company's valuation analysis indicates a significant upside potential, as evidenced by a lowered price target of $40, reflecting robust net present value despite acknowledging inherent risks in biotech investing. Furthermore, the increasing incidence of idiopathic pulmonary fibrosis (IPF), with over 40,000 new cases diagnosed annually, highlights a growing market need for effective therapies, further supporting a favorable outlook for GRI Bio's product candidates.
Bears say
GRI Bio Inc reported a net loss of $3.9 million, translating to an earnings per share (EPS) of $(7.72), which significantly exceeded both the company's estimates of $(4.08) and the consensus estimate of $(5.44). The financial report highlights significant balance sheet and liquidity risks, coupled with uncertainties surrounding the success of its product candidates in clinical trials and their ability to gain regulatory approval. Additionally, the company faces challenges related to commercialization, competition, and fluctuating investor sentiment towards biotech stocks, all of which contribute to a negative outlook on its stock performance.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares